

9th January, 2018

To
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001.

To,
National Stock Exchange of India Limited
“Exchange Plaza”,
Bandra - Kurla Complex,
Bandra(E), Mumbai – 400 051

Scrip Code: 532637

Symbol: MANGALAM

Sub:Statement of Investor Complaints as per Regulation 13(3) of SEBI (Listing Obligation and Discloure Requirement) Regulations, 2015 for the Quarter ended 31st December, 2017.


Dear Sir/Madam,

Pursuant to the provisions of Regulation 13(3) (Listing Obligation and Disclosure Requirement) Regulations, 2015, enclosed herewith is the Investor Grievance Report of our company for the Quarter ended 31st December, 2017.

Kindly take the same on your record.

Thanking You,

Your's Faithfully,
For **Mangalam Drugs & Organics Ltd**

Nikita Bavishi


Nikita Bavishi
Company Secretary



Investor Grievance Report under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations. 2015

Name of Company: Mangalam Drugs & Organics Ltd

Scrip Code: 532637

Symbol: MANGALAM

Quarter ending: 31st December, 2017

Particulars	Quarter ended 31.12.2017
INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	Nil
Received during the quarter	Nil
Disposed off during the quarter	Nil
Pending un-resolved at the end of the quarter	Nil

For Mangalam Drugs & Organics Ltd

Nikita Bavishi



Nikita Bavishi
Company Secretary

